Premier Alternatives

Alveus Therapeutics

Philadelphia, PA · Founded 2023 · Privately Held (backing)

Developer of biological and small-molecule treatments designed for metabolic disease management. Alveus Therapeutics is based in Philadelphia, PA and was founded in 2023. It was valued at $275 million at its early-stage round in Feb 2026, the last priced event on record. It has raised $202 million across 1 recorded round; the latest was a $56.9 million later-stage round in Dec 2025.

PMV mark · valuation
$275.2M
Oct 2026
Priced at
its early-stage round
Feb 2026
Total raised
$202.0M
Last round
Later Stage VC
Dec 2025

Alveus Therapeutics key facts

as of Oct 2026
  • Developer of biological and small-molecule treatments designed for metabolic disease management.
  • Alveus Therapeutics is valued at approximately $275.2M as of Oct 2026, set at its early-stage round, Feb 2026; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $202.0M across 1 recorded rounds; the latest was Later Stage VC ($56.9M) in Dec 2025.
  • Notable investors include Novo Holdings, Kurma Partners, Andera Partners, Omega Funds, Agent Capital — 13 tracked in total.
  • Status: Privately Held (backing).
PrivateMarketView mark
MEDIUM confidence
$275.2M

Valued at $275.2M at its early-stage round, Feb 2026. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Alveus Therapeutics with a free account
  • ·The complete investor list: 13 names
  • ·Watch Alveus Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Alveus Therapeutics funding rounds

1 rounds
Dec 2025Later Stage VC$56.9MSEC filing▮
Full funding history →

Alveus Therapeutics valuation

Alveus Therapeutics was valued at $275 million at its early-stage round in Feb 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Alveus Therapeutics raised?

Alveus Therapeutics has raised $202 million in total; 1 of its rounds is on record. The largest on record was a $56.9 million later-stage round in Dec 2025.

Alveus Therapeutics investors

13 investors are on record for Alveus Therapeutics, including Novo Holdings, Kurma Partners, Andera Partners and Omega Funds. The later-stage round in Dec 2025 drew 17 investors.

About Alveus Therapeutics

Developer of biological and small-molecule treatments designed for metabolic disease management. The company's platform combines genetic analysis, biological insights, and empirical data to develop dual-acting mechanisms, peptides, antibodies, and small molecules that target cardiometabolic dysfunctions, enabling the healthcare market to address therapeutic gaps in weight maintenance, treatment adherence, quality of weight loss, and long-term metabolic outcomes with reduced overlap.

Sector
Healthcare
HQ
Philadelphia, PA, United States
Founded
2023
Employees
28
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.